Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FRMM
Forum Markets
$5.16
-3.9%		$5.40
$1.76
▼
$174.60
$71.91M1.37337,008 shs86,857 shs
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.68
-4.5%		$1.79
$1.41
▼
$4.34
$75.07M0.15611,174 shs230,645 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$0.47
-2.3%		$0.72
$0.43
▼
$1.98
$15.50M1.58158,199 shs1.02 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.85
-4.1%		$2.68
$0.95
▼
$9.08
$69.80M1.431.48 million shs1.18 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FRMM
Forum Markets
-3.91%-9.95%-7.36%-11.79%+515,999,900.00%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-4.55%-4.00%-15.58%-10.64%+12.00%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-2.27%-22.74%-35.66%-48.12%-73.26%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-4.15%-10.19%-34.40%-42.72%+40.15%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FRMM
Forum Markets
$5.16
-3.9%		$5.40
$1.76
▼
$174.60
$71.91M1.37337,008 shs86,857 shs
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.68
-4.5%		$1.79
$1.41
▼
$4.34
$75.07M0.15611,174 shs230,645 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$0.47
-2.3%		$0.72
$0.43
▼
$1.98
$15.50M1.58158,199 shs1.02 million shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$1.85
-4.1%		$2.68
$0.95
▼
$9.08
$69.80M1.431.48 million shs1.18 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FRMM
Forum Markets
-3.91%-9.95%-7.36%-11.79%+515,999,900.00%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-4.55%-4.00%-15.58%-10.64%+12.00%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-2.27%-22.74%-35.66%-48.12%-73.26%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-4.15%-10.19%-34.40%-42.72%+40.15%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FRMM
Forum Markets
2.50
Moderate Buy$10.0093.80% Upside
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2.67
Moderate Buy$7.50346.43% Upside
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
2.60
Moderate Buy$8.501,727.17% Upside
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest NRSN, THAR, GANX, and FRMM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/21/2026
FRMM
Forum Markets
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/1/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00
6/30/2026
FRMM
Forum Markets
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/30/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
6/9/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
5/29/2026
FRMM
Forum Markets
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
5/27/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
5/15/2026
FRMM
Forum Markets
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSpeculative Buy$5.00 ➝ $9.00
5/12/2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/11/2026
FRMM
Forum Markets
Loop Capital logo
Loop Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$11.00
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FRMM
Forum Markets
$6.55M10.55N/AN/A$12.59 per share0.41
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$50K1,433.04N/AN/A$0.48 per share3.50
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A($0.05) per shareN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.68 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FRMM
Forum Markets
-$450.52M-$36.07N/A32.25N/AN/A-242.09%-135.46%N/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$11.12M-$0.54N/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%N/A

Latest NRSN, THAR, GANX, and FRMM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.14N/AN/AN/A$0.03 millionN/A
5/14/2026Q1 2026
FRMM
Forum Markets
N/A-$3.64N/A-$3.58N/A$2.86 million
5/11/2026Q1 2026
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.13-$0.13N/A-$0.13$0.03 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
FRMM
Forum Markets
N/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FRMM
Forum Markets
0.15
6.19
6.19
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.02
4.69
4.69
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
0.31
0.31
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
4.98
4.98

Institutional Ownership

CompanyInstitutional Ownership
FRMM
Forum Markets
4.07%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.04%
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%

Insider Ownership

CompanyInsider Ownership
FRMM
Forum Markets
25.20%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
4.15%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
27.40%
Tharimmune, Inc. stock logo
THAR
Tharimmune
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
FRMM
Forum Markets
713.39 million10.02 millionN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2042.65 million40.88 millionOptionable
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1032.56 million23.64 millionNot Optionable
Tharimmune, Inc. stock logo
THAR
Tharimmune
237.73 million35.20 millionNot Optionable

Recent News About These Companies

Tharimmune Investor Update Highlights Canton Network Growth, DTCC Pilot Momentum
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tharimmune-investor-update-highlights-canton-network-growth-dtcc-pilot-momentum-2026-07-22/
Tharimmune Stockholders Elect Board, Ratify Auditor at 2026 Annual Meeting
July 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/tharimmune-stockholders-elect-board-ratify-auditor-at-2026-annual-meeting-2026-07-13/
Tharimmune Inc.
May 13, 2026  |  wsj.comhttps://www.wsj.com/market-data/quotes/MX/XMEX/THAR
Tharimmune Rebrands as Canton Strategic Holdings, Updates Ticker
February 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tharimmune-rebrands-as-canton-strategic-holdings-updates-ticker?utm_source=marketbeat.com&utm_medium=referral
Is Canton’s price set to explode amid Tharimmune’s rebrand?
February 17, 2026  |  invezz.comI
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
February 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-inc-announces-corporate-rebrand-to-canton-strategic-holdings-inc-marking-milestone-in-canton-network-digital-asset-treasury-strategy-302689437.html
Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact
February 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/catherine-woods-strategic-moves-closer-230121661.html
Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
February 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-inc-appoints-mark-wendland-chairman-of-the-board-and-names-angela-radkowski-chief-operating-officer-302681307.html
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors
February 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-elects-jill-sommers-and-william-wiley-to-board-of-directors-302676288.html
Tharimmune Approved as Super Validator on Canton Network
January 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/THAR/pressreleases/37250744/tharimmune-approved-as-super-validator-on-canton-network/
Tharimmune Announces Expanded Role as Super Validator on Canton Network
January 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-announces-expanded-role-as-super-validator-on-canton-network-302670020.html
Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization
January 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4862112-tharimmune-inc-and-the-canton-network-a-privacy-focused-asymmetric-bet-on-tokenization
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
January 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-inc-announces-closing-of-55-million-underwritten-registered-direct-offering-302668522.html
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
January 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-inc-announces-pricing-of-55-million-underwritten-registered-offering-302665408.html
Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network
December 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-inc-statement-on-dtccs-initiative-to-tokenize-us-treasury-securities-on-the-canton-network-302645591.html
Tharimmune appoints Jacob Asbury as CFO
December 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/tharimmune-appoints-jacob-asbury-as-cfo/ar-AA1SeJkM
Tharimmune Appoints Jacob Asbury as New CFO
December 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tharimmune-appoints-jacob-asbury-as-new-cfo?utm_source=marketbeat.com&utm_medium=referral
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy
December 12, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251212841716/en/tharimmune-inc.-appoints-jacob-asbury-as-chief-financial-officer-to-advance-canton-coin-treasury-strategy/
Tharimmune files to sell 176.93M shares of common stock for holders
December 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tharimmune-files-to-sell-176-93m-shares-of-common-stock-for-holders/ar-AA1ROv8y
Crypto Company Creates Bizarre Drug
November 22, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/crypto-company-creates-bizarre-drug/ar-AA1QXHmn
Tharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?
November 22, 2025  |  defenseworld.netD

New MarketBeat Followers Over Time

Media Sentiment Over Time

Forum Markets NASDAQ:FRMM

$5.16 -0.21 (-3.91%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$5.35 +0.19 (+3.76%)
As of 07/31/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.68 -0.08 (-4.55%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$1.70 +0.02 (+1.19%)
As of 07/31/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$0.47 -0.01 (-2.27%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.43 -0.04 (-7.57%)
As of 07/31/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$1.85 -0.08 (-4.15%)
As of 07/30/2026

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas